The UK’s Cell Therapy Catapult program has got the ball rolling on a new £55-million manufacturing center designed to “crack the nut” on the scale up, manufacturing and distribution challenges of cell therapies. The aim is to help companies to take their cell therapies from pilot scale to the commercial scale – and the investment comes from Innovate UK, the UK’s innovation agency, after the Cell Therapy Catapult identified a number of gaps hindering cell therapy progress. The center will be located in Stevenage and is set to be fully functional by 2017 – with 5,500m2 of cleanroom space and 12 segregated cleanroom units. We spoke with Matthew Durdy, Chief Business Officer at Cell Therapy Catapult to find out more about the project.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
